Literature DB >> 16191005

Debridement via collagenase application in two neonates.

Ulku Tiras1, Omer Erdeve, Ayse Anil Karabulut, Yildiz Dallar, H Meral Eksioglu.   

Abstract

Slow-healing wounds contain insufficient amounts of intrinsic collagenases to provide sufficient wound debridement, so that the use of products containing synergistic collagenases and proteases may be helpful. We report the successful use of collagenase clostridipeptidase A in two newborns, a premature infant with 3rd degree burns, and a term neonate with an extravasation necrosis caused by calcium gluconate. Surgical excision of necrotic tissue is a serious intervention and prolongs the duration of hospitalization. Enzymatic eschar removal may have an advantage over surgery especially in newborns with a high risk for surgery, with its possible complications, need for anesthesia, and perhaps for blood transfusion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16191005     DOI: 10.1111/j.1525-1470.2005.00119.x

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  4 in total

1.  Collagenase for Wound Debridement in the Neonatal Intensive Care Unit: A Retrospective Case Series.

Authors:  Elizabeth Huett; Whitney Bartley; Darla Morris; Della Reasbeck; Beth McKitrick-Bandy; Charlotte Yates
Journal:  Pediatr Dermatol       Date:  2017-05       Impact factor: 1.588

2.  Neonatal Burns - A Romanian Experience From A Tertiary Care Burn Unit.

Authors:  A Muntean; I Stoica; R Tatar; D M Enescu
Journal:  Ann Burns Fire Disasters       Date:  2022-03-31

3.  Cohnella 1759 cysteine protease shows significant long term half-life and impressive increased activity in presence of some chemical reagents.

Authors:  Rayan Saghian; Elham Mokhtari; Saeed Aminzadeh
Journal:  Sci Rep       Date:  2021-02-25       Impact factor: 4.379

4.  Effects of topical Kiwifruit on healing of neuropathic diabetic foot ulcer.

Authors:  Gholamreza Mohajeri; Masumeh Safaee; Mohamad Hossein Sanei
Journal:  J Res Med Sci       Date:  2014-06       Impact factor: 1.852

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.